|Year : 2022 | Volume
| Issue : 2 | Page : 89-90
Has treatment for all cancers arrived?
Rajendra B Nerli1, Shadab Rangrez2
1 Department of Urology, JN Medical College, KLE Academy of Higher Education and Research (Deemed-to-be-University), Belagavi, Karnataka, India
2 Department of Urology, Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital and M.R.C., Belagavi, Karnataka, India
|Date of Submission||09-Jul-2022|
|Date of Acceptance||18-Jul-2022|
|Date of Web Publication||23-Aug-2022|
Rajendra B Nerli
Department of Urology, JN Medical College, KLE Academy of Higher Education and Research (Deemed-to-be-University), JNMC Campus, Belagavi - 590 010, Karnataka
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Nerli RB, Rangrez S. Has treatment for all cancers arrived?. J Sci Soc 2022;49:89-90
Recently, in June 2022, a sensation was created by the news of a miracle drug that cured all patients with cancer in a drug trial. A small clinical trial discovered that every single rectal cancer patient who got an experimental treatment saw their disease vanish, in what looks to be a miracle and a “first in history.” According to the New York Times, 18 patients took a medicine named dostarlimab for 6 months in a limited clinical trial done by Memorial Sloan Kettering Cancer Center, and all of them saw their tumors shrink at the end. Cancer experts stated that the malignancy was undetectable by physical examination, endoscopy, positron emission tomography scans, or magnetic resonance imaging scans. This showed that dostarlimab had the potential to be a “possible” cancer cure for one of the most lethal tumors.
Dostarlimab is a monoclonal antibody used as a medication for the treatment of cancer., It is a programmed death receptor-1–blocking monoclonal antibody.,, Dostarlimab received approval for its medical use in the United States and the European Union in April 2021. The Food and Drug Administration granted accelerated approval to dostarlimab-gxly, for use in adult patients with deficient mismatch repair (dMMR) recurrent or advanced solid tumors, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. The ongoing phase 1 GARNET study (NCT02715284) has been evaluating dostarlimab in patients with advanced solid tumors. Early analysis demonstrated durable antitumor activity in a cohort of dMMR solid tumor patients, the majority of whom had gastrointestinal cancers.
We all know that India's cancer growth rates are among the highest in the globe, as per the Cancer Statistics report. Cancer cases have increased at an average annual rate of 1.1–2 per cent from 2010 to 2019. Although the above-mentioned clinical trial included only 18 patients with rectal cancer, who were put on immunotherapy for 6 months, this brings us to the question if we can finally hope for cancer treatment for all cancers? Is the cancer cure near or will we still have to wait before the cure reaches all?
This trial proves the concept of tailoring cancer treatment according to individual patient needs. This trial drug (dostarlimab) however may not be the panacea for all cancers. Dostarlimab is an immunotherapy drug. Immunotherapy drugs have become another pillar of cancer care in recent years. There are many drugs (pembrolizumab, nivolumab, atezolizumab, ipilimumab, etc.) similar to dostarlimab in the market now including Indian market. However, all these drugs are meant for very specific indications.
| References|| |
Kasherman L, Ahrari S, Lheureux S. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol 2021;17:877-92.
Andre T, Berton D, Curigliano G, Ellard S, Perez J, Arkenau H et al
. Available from: “https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.9
” Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. J Clin Oncol 2021;39:3_suppl, 9-9.